ArticleHarm reduction journal2026
Zeroing in on xylazine - a mixed methods study to explore correlates of reported xylazine use and educational gaps among people who use drugs.
Article in Harm reduction journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundXylazine prevalence has surged in the unregulated fentanyl supply across the United States. In efforts to inform education initiatives for people who use drugs, this study aimed to identify factors associated with reported xylazine use and knowledge gaps.
methodsThis Connecticut-based mixed methods study employed both surveys and interviews. Survey participants, recruited from collaborating harm reduction organizations, were adults who used unregulated substances in the last six months. They were asked about their drug use, knowledge of xylazine, service use experience, and demographic information. Purposive sampling of survey participants was then used to select individuals for in-depth interviews. Topic guides were designed to gain a deeper understanding of participants' xylazine awareness and future learning preferences. Quantitative data were dichotomized based on reported xylazine use and analyzed using descriptive statistics, Chi-square, Fisher's exact, or t-tests. Simple and multiple logistic regression were used to find correlates of reported use of xylazine. Interviews were analyzed using thematic analysis.
resultsBetween August and November 2024, we surveyed 114 respondents. Nearly half reported lifetime xylazine use (49.1%) and almost three-quarters heard of xylazine prior to engaging in the study (71.9%). Multiple logistic regression revealed that unemployment (OR 6.5, 95% CI 2.4-17.8), past-year fentanyl use (OR 41.1, 95% CI 4.8-354.4), and harm reduction service engagement (OR 5.2, 95% CI 1.6-16.8) as predictors of reported xylazine use, after adjustments. We conducted n=31 interviews; thematic analysis identified four major themes: (1) information about xylazine was obtained from many sources, (2) knowledge about xylazine was gained from using xylazine, (3) some misconceptions about xylazine have developed, and (4) multiple mechanisms for xylazine education are desired.
conclusionsThis study underscores the need for accessible xylazine education to address knowledge and confidence gaps among people who use drugs. Xylazine education should be tailored to one's likely xylazine exposure. Education must be harm-reduction oriented, stigma-free, and incorporate the voices of people who use drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.